journal article·2026-07Open access

A biomimetic oxygen-generating nanoplatform for enhanced sonodynamic immune activation

Haiqin Liao, Shiyu Ding, Ming Zhang, Quanliang Shang, Zhigang Wang

Abstract

Background Sonodynamic therapy (SDT) has emerged as a promising strategy for cancer treatment; however, its therapeutic efficacy is significantly limited by the hypoxic tumor microenvironment, particularly in breast cancer. To address this limitation, we developed a biomimetic nanoplatform capable of generating oxygen within the tumor microenvironment to enhance SDT performance. Methods Poly (lactic-co-glycolic acid) (PLGA) nanoparticles were co-loaded with catalase and the sonosensitizer IR780 and subsequently coated with 4T1 cancer cell membranes (CIP@4T1m NPs). A series of in vitro and in vivo experiments were conducted to evaluate tumor-targeting capability, hypoxia alleviation, singlet oxygen ( 1 O 2 ) generation, antitumor efficacy, induction of immunogenic cell death (ICD), and activation of antitumor immune responses. Results The resulting CIP@4T1m NPs were successfully fabricated and exhibited preferential accumulation in 4T1 tumor cells and orthotopic 4T1 tumor-bearing mice. Both in vitro and in vivo studies demonstrated that the nanoplatform partially relieved tumor hypoxia and significantly enhanced SDT-mediated 1 O 2 production and antitumor effects. Moreover, CIP@4T1m NPs combined with ultrasound induced ICD-associated changes, promoted dendritic cell maturation, facilitated the polarization of tumor-associated macrophages from the M2 to M1 phenotype, reduced regulatory T cell populations, and increased intratumoral CD8 + T-cell infiltration. Conclusion This work describes a biomimetic nanoplatform that integrates homologous targeting with enzymatic oxygen generation to enhance SDT efficacy and promote antitumor immune responses in an orthotopic 4T1 breast cancer model. The proposed strategy offers a potential approach to mitigate hypoxia-associated limitations in cancer therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Ultrasound and Hyperthermia Applications · Cancer, Hypoxia, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The Second Affiliated Hospital of Chongqing Medical University

The Second Xiangya Hospital, Central South University

Clinical Research Center for Ultrasound and Treatment in Hunan Province

The First School of Clinical Medicine, Hunan University of Chinese Medicine

Funding

Joint Project of Pinnacle Disciplinary Group, the Second Affiliated Hospital of Chongqing Medical University

References (29)

Show source-provided references
1. 10.3322/caac.2182010.3322/caac.21820 ↗
2. 10.1200/JCO.2008.17.716210.1200/JCO.2008.17.7162 ↗
3. 10.1002/adma.20200321410.1002/adma.202003214 ↗
4. 10.1038/s41467-023-42509-710.1038/s41467-023-42509-7 ↗
5. 10.1002/advs.20230539210.1002/advs.202305392 ↗
6. 10.1038/s41563-023-01721-y10.1038/s41563-023-01721-y ↗
7. 10.1038/nrc338010.1038/nrc3380 ↗
8. 10.1039/D1TB00407G10.1039/D1TB00407G ↗
9. 10.1186/s12951-025-03485-w10.1186/s12951-025-03485-w ↗
10. 10.1007/s10555-007-9056-010.1007/s10555-007-9056-0 ↗
11. 10.1016/j.biomaterials.2019.01.00210.1016/j.biomaterials.2019.01.002 ↗
12. 10.1021/jacs.5c0084310.1021/jacs.5c00843 ↗
13. 10.1016/j.biomaterials.2020.11975510.1016/j.biomaterials.2020.119755 ↗
14. 10.1002/adma.20190073010.1002/adma.201900730 ↗
15. 10.1038/s41571-022-00699-x10.1038/s41571-022-00699-x ↗
16. 10.1021/acsnano.2c0089310.1021/acsnano.2c00893 ↗
17. 10.1039/D5BM00189G10.1039/D5BM00189G ↗
18. 10.1016/j.biomaterials.2023.12245610.1016/j.biomaterials.2023.122456 ↗
19. 10.1038/s41573-024-00920-910.1038/s41573-024-00920-9 ↗
20. 10.1002/adma.20210403710.1002/adma.202104037 ↗
21. 10.1021/acs.nanolett.8b0356810.1021/acs.nanolett.8b03568 ↗
22. 10.1002/adma.20230383510.1002/adma.202303835 ↗
23. 10.1002/adma.20200485310.1002/adma.202004853 ↗
24. 10.1002/adma.20231367010.1002/adma.202313670 ↗
25. 10.1038/s41392-023-01332-810.1038/s41392-023-01332-8 ↗
26. 10.1136/jitc-2023-00802610.1136/jitc-2023-008026 ↗
27. 10.1016/j.trecan.2023.09.00610.1016/j.trecan.2023.09.006 ↗
28. 10.1186/s12943-023-01885-w10.1186/s12943-023-01885-w ↗
29. Gu JLY, Chen Q, Song Z, et al. Tumor-produced ammonia is metabolized by regulatory T cells to further impede anti-tumor immunity. Cell 2025; S0092-8674(25): 01368–01369. https://doi.org/10.1016/j.cell.2025.11.034